Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Status:
Terminated
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
The purpose of phase I trial is to determine the safest, most effective dose of MK-3475
(pembrolizumab), when used with radiotherapy and temozolomide for treating newly diagnosed
patients with glioblastoma (GBM). Temozolomide binds to the deoxyribonucleic acid (DNA),
changes it, and triggers the death of tumor cells. MK-3475 is an investigational drug, it is
not currently approved by the Federal Drug Administration (FDA) for use in treating GBM but
it is approved for treating melanoma. MK-3475 works by targets the local tumor
immune-protection in solid tumors. It is hoped the addition of MK-3475 to the usual treatment
for GBM will improve the current treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Northwestern University
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)